Histone deacetylase–mediated regulation of endolysosomal pH

Hari Prasad¹ and Rajini Rao²

From the Department of Physiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Edited by John M. Denu

The pH of the endolysosomal system is tightly regulated by a balance of proton pump and leak mechanisms that are critical for storage, recycling, turnover, and signaling functions in the cell. Dysregulation of endolysosomal pH has been linked to aging, amyloidogenesis, synaptic dysfunction, and various neurodegenerative disorders, including Alzheimer’s disease. Therefore, understanding the mechanisms that regulate luminal pH may be key to identifying new targets for managing these disorders. Meta-analysis of yeast microarray databases revealed that nutrient-limiting conditions inhibited the histone deacetylase (HDAC) Rpd3 and thereby up-regulated transcription of the HDAC inhibitor and antifungal drug trichostatin A induced Nhx1 expression and vacuolar alkalization. Bioinformatics analysis of Drosophila and mouse databases revealed that caloric control of the Nhx1 orthologs DmNHE3 and NHE6, respectively, is also mediated by HDACs. We show that NHE6 is a target of the transcription factor cAMP-response element–binding protein (CREB), a known regulator of cellular responses to low-nutrient conditions, providing a molecular mechanism for nutrient- and HDAC-dependent regulation of endosomal pH. Of note, pharmacological targeting of the CREB pathway to increase NHE6 expression helped regulate endosomal pH and correct defective clearance of amyloid Aβ in an apoE4 astrocyte model of Alzheimer’s disease. These observations from yeast, fly, mouse, and cell culture models point to an evolutionarily conserved mechanism for HDAC-mediated regulation of endosomal pH expression. Our insights offer new therapeutic strategies for modulation of endolysosomal pH in fungal infection and human disease.

The endosome is a busy way station that handles cargo traffic at the cross-roads of degradation and recycling. An important hallmark of the endolysosomal system is a pH gradient that increases acidification through the transition from early, recycling, and late endosomes to the lysosome (1). Precise tempo-spatial pHlumen regulation within each of these specialized compartments is critical for a range of functions, including controlling cargo sorting, vesicular budding and formation of intraluminal vesicles, dissociation of internalized ligands, receptor recycling and turnover, modulating enzyme activity, antigen processing, and cellular signaling (2).

Endosomes are acidified by the electrogenic pumping of protons by the V-type H⁺-ATPase in conjunction with vesicular chloride transporters of the CLC family that shunt the membrane potential, effectively allowing a build-up of luminal protons (3, 4). Proton leak mechanisms consisting of proton conductance channels or proton-coupled antiporters limit the acidification, and the balance of pump and leak pathways defines the pH set point. Although the molecular identity of vesicular proton channels remains poorly defined, more recently, endosomal Na⁺/H⁺ exchangers (eNHE)³ have emerged as the dominant leak pathway for luminal protons. Because exchanger mechanisms have high transport rates of ∼1,500 ions/s (5), they overwhelm the capacity of the proton pump so that even small changes in eNHE activity or expression result in significant pH changes within the endolysosomal system.

The fundamental importance of endosomal pH is highlighted by the fact that a growing number of human diseases are associated with mutations in V-ATPase subunits (e.g. osteopetrosis, renal tubular acidosis, cutis laxa), chloride transporters (e.g. Dent’s disease), and eNHE (Christianson syndrome, autism, and attention deficit hyperactivity disorder) (3, 4, 6). Furthermore, defective endolysosomal pH regulation is being increasingly linked to cellular aging, amyloidogenesis, synaptic dysfunction, and neurodegenerative disorders, including Alzheimer’s disease (7, 8). Therefore, the discovery of novel regulators of endolysosomal pH may be crucial to identifying new diagnostic and therapeutic targets for these disorders.

As a starting point, we turned to the yeast Saccharomyces cerevisiae, which has powerfully informed our understanding of fundamental mechanisms of endocytosis and vesicular traffic that are functionally conserved with higher organisms (9). By
leverage data from yeast to fly and mammalian models, we discovered an evolutionarily conserved mechanism for epigenetic control of eNHE by histone deacetylases (HDACs) in response to nutrient availability. In mammalian cells, HDAC-mediated control of endolysosomal pH occurs by transcriptional regulation of the endosomal Na⁺/H⁺ exchanger NHE6 (SLC9A6) via the cAMP-response element–binding protein (CREB) pathway. We show that elevation of cAMP levels by the FDA-approved drug Rolipram results in CREB activation, increased NHE6 expression, and restoration of defective Aβ clearance in the apoE4 astrocyte model of late onset Alzheimer’s disease.

Histone acetylation has been widely recognized as a key modulator of global chromatin structure that dynamically couples extracellular signals to gene transcription. Whereas lysine acetylation on histone tails interferes with generation of higher-order chromatin structures and promotes access and binding of transcription factors, histone deacetylation favors chromatin packing and represses gene transcription (10–12). HDAC inhibitors have been approved for the treatment of hematologic cancers and are being considered as a promising therapy to reverse disease-associated epigenetic states in a range of cardiovascular, neurodegenerative, and inflammatory diseases (11–14). Given their broad application, our findings offer potential therapeutic options to treat endolysosomal pH dysfunction in autism, AD, and other neurodegenerative disorders.

Results

**Nutrient control of endolysosomal pH in yeast**

Yeast microarray data sets are a valuable resource for discovery-driven mining efforts. A meta-analysis of 45 microarray experiments that included 937 samples revealed increasing expression of Nhox1, with growth phase stationary > mid-log >
Histone deacetylases control endolysosomal pH

Figure 2. Discovery of the Rpd3-Abf1 axis for regulation of Nhx1 expression by histone deacetylases. A, waterfall plot depicting -fold change in Nhx1 expression (y axis) obtained from an unbiased bioinformatics analysis of 284 microarray studies (x axis), as described under “Experimental procedures.” Note that all five conditions leading to maximal down-regulation of Nhx1 were linked to depletion of Abf1 transcription factor, known to be negatively regulated by Rpd3. B, HDAC activity of Rpd3 was common to all three microarray experiments that gave maximal up-regulation of Nhx1 expression, namely (i) genetic deletion of Rpd3, (ii) glucose depletion, and (iii) nitrogen depletion. C, HDAC–Rpd3–Abf1–Nhx1 axis for regulation of Nhx1 expression. This model predicts that inhibition of Rpd3 activity releases the brake on Abf1, which in turn binds to the Abf1-binding site (ABS) on the Nhx1 promoter and enhances its expression. See related Fig. S1.

early log (Fig. 1A), which we independently confirmed; Nhx1 transcript increased by 3.2-fold in stationary-phase cells, compared with mid-log phase (Fig. 1B). Stationary-phase growth in yeast is associated with depletion of nutrients. To determine whether growth-phase regulation of Nhx1 was linked to glucose availability, we tested the effect of glucose removal from mid-log phase yeast cultures. Nhx1 mRNA was increased by nearly 2-fold within 60 min of glucose removal (p < 0.001; Fig. 1C). In contrast, the addition of glucose (2%) to stationary-phase cultures elicited significant decrease in Nhx1 mRNA within 30 min (p < 0.001; Fig. 1D).

Nhx1 functions as a leak pathway for protons within the endosome/prevacuolar compartment, in opposition to the proton pump activity of the V-ATPase (15) (Fig. 1E). The balance of proton pump and leak sets the pH within the endolysosomal compartments. Therefore, we also analyzed expression of V-ATPase subunits under the same experimental conditions. Although we did not observe a growth phase–dependent transcriptional change in the V-ATPase catalytic subunit Vma1 (Fig. 1B), V-ATPase subunits were significantly down-regulated with acute glucose depletion (p < 0.001, Vma1; p < 0.001, Vma7; Fig. 1C) and up-regulated upon glucose addition (p < 0.05, Vma1; p < 0.001, Vma7; Fig. 1D) in contrast to Nhx1.

Previous studies have shown that yeast V-ATPase subunit Stv1 is selectively targeted to the Golgi/secretory pathway and is not required for vacuolar acidification and function (16, 17). In contrast to Vma1 and Vma7, Stv1 expression showed modest or no changes in response to glucose (Fig. 1, C and D), suggesting that the effect of glucose regulation on the V-ATPase is largely localized to late endosomal/vacuolar compartments.

We predicted that reciprocal transcriptional changes in Nhx1 and V-ATPase subunits would alter the pH of the yeast vacuole. Vacuolar pH can be probed in situ with the pH-sensitive fluorescent dye quinacrine, which accumulates in acidic environments (18). Following glucose depletion, yeast vacuoles showed little or no quinacrine staining, similar to V-ATPase–deficient vma7Δ mutants (Fig. 1, F and G; p < 0.0001, n = 100). Consistent with the potential role for Nhx1 in regulating nutrient control of endolysosomal pH in yeast, nhx1Δ mutants showed severely reduced survival during the stationary-phase growth (19). Post-translational regulation of V-ATPase disassembly and reassembly in response to glucose concentration is well established (20, 21). Here, we conclude that glucose also elicits reciprocal transcriptional changes in proton pump and leak mechanisms to regulate the pH gradient across yeast vacuoles.

Regulation of endolysosomal pH in yeast is mediated by a histone deacetylase

We extended our unbiased bioinformatics approach to analyze data from 284 microarray studies that comprised a wide range of experimental conditions, including gene deletion, overexpression, and mutations; drug/toxin treatment; nutrient limitation or excess; metabolic/environmental stress; and more. We identified experimental conditions eliciting a minimum of ±2-fold change in NHX1 gene expression (Fig. 2A and Fig. S1A). The highest up-regulation of Nhx1 was observed under conditions of (i) genetic deletion of Rpd3, (ii) glucose depletion, and (iii) nitrogen depletion. Pathway analysis revealed that loss or inhibition of HDAC activity of Rpd3 was common to all three of these conditions (22, 23) (Fig. 2B). Thus, nutrient (glucose or nitrogen) depletion preserves histone acetylation by replacement and inactivation of the HDAC-Rpd3 complex from the promoters of specific genes (22). Consistent with this finding, Rpd3 deletion phenocopies calorie restriction by enhancing lifespan of yeast cells (24, 25). Conversely, all five conditions leading to maximal down-regulation of Nhx1 were linked to depletion of Abf1, an essential transcription factor that is negatively regulated by Rpd3 (26–28) (Fig. 2A and Fig. S1A). Recent evidence suggests that Abf1 is activated during nutritional stress (29). Furthermore, Abf1 is predicted to bind to the NHX1 promoter (Fig. S1B), and chromatin immu-
noprecipitation with DNA microarray (ChIP-on-chip) data from the Saccharomyces Genome Database (SGD) provided experimental evidence for Abf1 binding to the \textit{NHX1} promoter (30). For comparison, depletion of another general regulatory transcription factor, Rap1, had no effect on Nhx1 expression (Fig. 2A and Fig. S1A). Although more direct studies are needed to confirm Rpd3-Abf1 occupancy of the \textit{NHX1} promoter, bioinformatics analysis of all top hits in \textit{NHX1} gene expression (both up- and down-regulation) funneled into a single pathway: the Rpd3-Abf1-Nhx1 axis (Fig. 2C).

To confirm and extend these \textit{in silico} observations, we independently demonstrated that Nhx1 transcript was elevated by 1.9-fold in the \textit{rpd3}/H9004 mutant, relative to isogenic WT yeast (Fig. 3A). Other histone deacetylase gene deletions conferred more modest induction (1.35-fold in \textit{hda1}; Fig. 3A) or repression (0.6-fold in \textit{sr2}; Fig. 3A). All three yeast deletion strains showed similar growth (Fig. S2A). Restoration of Rpd3 by ectopic expression under a galactose-inducible promoter in \textit{rpd3}/H9004 not only abolished Nhx1 up-regulation in stationary phase, but also caused further repression (68% lower) in mid-logarithmic cells and inhibited yeast growth (Fig. S2, B and C).

Yeast Rpd3 is a target of the histone deacetylase inhibitor and fungal antibiotic trichostatin A (TSA). We show that that TSA treatment of WT yeast elicited significant 2.9-fold up-regulation of Nhx1 transcript (Fig. 3B), mimicking the effect of Rpd3 deletion. In contrast, we observed significant down-regulation of V-ATPase subunits Vma1 (~30% lower; Fig. 3C) and Vma7 (~37% lower; Fig. 3D) in TSA-treated yeast, compared with vehicle treatment. In contrast to Vma1 and Vma7, the levels of Stv1 did not change significantly with TSA treatment (Fig. S2D), suggesting that the effect of TSA is specific to V-ATPase localized to the vacuolar compartment.

Figure 3. Regulation of endolysosomal pH in yeast is mediated by a histone deacetylase. A, deletion of Rpd3 (\textit{rpd3}/\textit{rpd3}) strain) increased \textit{NHX1} transcript by 1.9-fold relative to isogenic WT yeast (\textit{**}, \textit{p} = 0.0002; \textit{n} = 3; Student's \textit{t} test). Deletion of two other histone deacetylase genes led to lesser \textit{NHX1} induction (1.35-fold in \textit{hda1}; \textit{***}, \textit{p} = 0.0003; \textit{n} = 3; Student's \textit{t} test) or repression (0.6-fold in \textit{sr2}; \textit{***}, \textit{p} = 0.0003; \textit{n} = 3; Student's \textit{t} test). B, TSA treatment of WT yeast elicited significant 2.88-fold up-regulation of Nhx1 transcript (\textit{**}, \textit{p} = 0.001; \textit{n} = 3; Student's \textit{t} test) mimicking the effect of Rpd3 deletion. C and D, qPCR analysis of V-ATPase subunits showed significant down-regulation of Vma1 (~30% lower; \textit{***}, \textit{p} = 0.0003; \textit{n} = 3; Student's \textit{t} test) and Vma7 (~37% lower; \textit{**}, \textit{p} = 0.001; \textit{n} = 3; Student's \textit{t} test) in TSA-treated yeast, compared with vehicle treatment. E and F, representative micrographs (E) and quantification (F) showing loss of quinacrine fluorescence with TSA treatment, similar to treatment with a V-ATPase inhibitor concanamycin A (ConA), pointing to increased vacuolar alkalization (\textit{***}, \textit{p} < 0.0001; \textit{n} = 100; Student's \textit{t} test). G, alkaline pH sensitivity is a defining phenotype of increased vacuolar pH. TSA-treated cells show dose-dependent reduction of growth at medium pH of 7.0 as compared with pH of 4.3 (\textit{***}, \textit{p} < 0.001; \textit{n} = 4; Student's \textit{t} test). H, a spotting assay on YPD agar plates was performed to demonstrate hypersensitivity to TSA in the \textit{vma7Δ} yeast, lacking V-ATPase activity, indicative of synthetic lethality. See related Fig. S2. Error bars, S.D.
The transcriptional up-regulation of Nhx1 and concomitant down-regulation of vacuolar V-ATPase subunits by TSA is predicted to alkalinize the yeast vacuole (3). Compared with robust quinacrine fluorescence in WT yeast vacuoles (18), TSA treatment drastically reduced vacuolar accumulation of quinacrine, similar to the effect of the well-characterized V-ATPase inhibitor concanamycin A, pointing to increased vacuolar pH (Fig. 3, E and F). Alkaline pH sensitivity is a defining phenotype of V-ATPase mutants, indicative of the reduced ability to acidify vacuoles (31, 32). We found that TSA-treated cells show dose-dependent reduction of growth at alkaline medium pH (Fig. 3G). Hypersensitivity to TSA in the vma7Δ yeast, lacking V-ATPase activity, is evidenced by synthetic lethality (Fig. 3H and Fig. S2E). TSA synergizes with the antifungal action of an azole drug fluconazole that we previously showed to act via inhibition of V-ATPase activity (31)(Fig. S2F). Together, these data provide strong evidence for regulation of yeast vacuolar pH by HDAC inhibition.

**Evolutionary conservation of eNHE regulation by nutrient availability and histone deacetylases**

To investigate whether the mechanism of up-regulation of eNHE in response to nutrient limitation and HDAC activity is evolutionarily conserved, we evaluated publicly available expression data in the fruit fly Drosophila melanogaster. Fruit fly has one eNHE isoform, DmNHE3, which, like its mammalian cousin NHE6, is highly expressed in the brain (33) (Fig. 4A). Analysis of a microarray data set studying the effects of starvation in Drosophila larvae (GSE14531) revealed significant down-regulation of class I HDAC DmRpd3 (−2.14-fold; **, p = 0.0012; n = 3; Student’s t test; B) and reciprocal up-regulation of class III HDAC DmSir2 (1.66-fold; **, p = 0.0017; n = 3; Student’s t test; C) in fly larvae starved for 24 h. D, significant up-regulation (2.12-fold; **, p = 0.0017; n = 3; Student’s t test) of DmNHE3 expression with starvation suggests an evolutionarily conserved mechanism for regulation of eNHE expression by histone deacetylases in yeast and fly models. See related Fig. S3. Error bars, S.D.
Histone deacetylases control endolysosomal pH

Figure 5. Calorie restriction and HDAC inhibition increase NHE6 expression. A, schematic to show that dietary calorie restriction mimics the effects caused by HDAC inhibitors (HDACI) and predicted to alter eNHE expression. B, calorie restriction (~10% lower than ad libitum intake) in the mouse significantly increased NHE6 expression in the neocortex (*, p = 0.01; n = 5; Student’s t test). C and D, gene expression data from two independent microarray experiments studying the effect of TSA in cell culture at shorter (2 h) and longer (18 h) time points. TSA treatment significantly increased NHE6 expression in the neocortex (*, p = 0.011; *, n = 3; Student’s t test; 2 h; C) (**, p = 0.00046; n = 4; Student’s t test; 18 h; D) at both time points. See related Figs. S4 and S5.

HDAC inhibitors, including on histone acetylation and activation of CREB (36–39). Intriguingly, the mammalian eNHE ortholog NHE6 is a reported insulin-responsive protein, and its subcellular trafficking is regulated by insulin (40). Furthermore, in neurons, loss of NHE6 has been reported to attenuate brain-derived neurotrophic factor (BDNF) signaling that is downstream of insulin and the CREB cascade (41, 42). Given that Na+/H+ exchangers are estimated to have very high transport rates of ~1,500 ions/s (5), even small changes in expression may be functionally significant. Therefore, to test whether calorie restriction or HDAC inhibitors enhance mammalian eNHE expression, we first analyzed publicly available expression data on caloric restriction (~10% lower than ad lib intake) in the mouse (Fig. 5A). These data revealed significant up-regulation of NHE6 in the neocortex (Fig. 5B) but not of the closely related endosomal NHE9 or V-ATPase subunit Vma1/ATP6V1A (Fig. S4, A and B) (43). Next, we analyzed two independent microarray experiments studying the effect of TSA in cell culture at shorter (2 h; GSE8488) and longer (18 h; GSE9247) time points (44, 45). Expression data from both of these experiments revealed significant up-regulation of NHE6 with TSA treatment (Fig. 5, C and D), but not NHE9 (Fig. S5, A–D) or NHE1 (Fig. S5, B–E). Activation of transcription factor CREB is a common response to both calorie restriction and pharmacological HDAC inhibition (12, 39). Thus, for comparison, we evaluated a prototypic CREB target BDNF and documented significant up-regulation with calorie restriction in mice (Fig. S4C) and HDAC inhibition in cell culture (Fig. S5, C–F), as predicted. These observations from yeast, fly, mouse, and cell culture models support our hypothesis of an evolutionarily conserved mechanism for regulation of eNHE expression by histone deacetylases.

NHE6 is a transcriptional target of CREB

Next, we attempted to identify the HDAC-regulated transcription factor equivalent to yeast Abf1 in higher eukaryotes. In the absence of direct Abf1 orthologs in the Drosophila or human genome, we looked for parallel starvation response pathways between human and yeast. Various studies suggest that CREB transcription factor regulates the response to nutrient deprivation and glucose availability in mammalian cells, analogous to the Abf1 transcription factor in yeast (39, 46). Both class I (HDAC1) and class II (HDAC4) HDACs directly interact with CREB and negatively regulate its function (47, 48). Furthermore, similar to the Abf1 transcription factor in yeast, the phosphorylation state of CREB is tightly regulated in response to nutrient and glucose availability (39, 49). Based on all of these observations, we hypothesized NHE6 as a potential CREB target (Fig. 6A).

Analysis of a publicly available data set of CREB target genes, from ChIP with DNA microarray (ChIP-on-chip) (50), using the recommended cutoff for ChIP-positive genes (binding ratio ≥1.5 and log10 p value ≥3) revealed NHE6 as a potential CREB target. The ChIP binding data for NHE6 were similar to those of DUSP1, a known CREB target, whereas no CREB occupancy was detected for the related NHE7 isoform (Fig. 6, B and C). Consistent with our hypothesis in Fig. 6A, TSA treatment resulted in a ~5.2-fold increase in NHE6 expression in HEK293 cells (Fig. 6D), whereas, modest increases were observed in NHE7 (~1.3-fold; Fig. S6A) and NHE9 (~1.4-fold; Fig. 6D), and no changes in expression of V-ATPase subunits V0a1 (lysosomal) and V0a2 (putative endosomal) were observed (Fig. S6, B and C). We used the firefly and Renilla luciferase reporter gene system to demonstrate significant activation of cAMP-response element (CRE) with TSA treatment (10 µM, 12 h), relative to vehicle control (p = 0.0064; Fig. 6, D and E). To establish a causal link between CREB activation and NHE6 expression, we treated HEK293 cells with forskolin, an adenylyl cyclase activator, and confirmed a significant increase in NHE6 transcript levels that was blocked by expression of a constitutively active/nuclear HDAC4 mutant (S246A/S467A/S632A) (Fig. 6G).

To directly test whether NHE6 is a CREB target, we expressed FLAG-tagged CREB1 plasmid in HEK293 cells and assessed (i) functional expression of NHE6 and (ii) binding of
CREB to the NHE6 promoter by ChIP-qPCR (Fig. 7A). Expression of CREB1 in HEK293 cells significantly elevated NHE6 transcript (Fig. 7B), resulting in alkalization of endosomal pH from 5.9 ± 0.03 to 6.12 ± 0.05 (Fig. 7C). In contrast, no changes in NHE6 transcript or endosomal pH were observed with the nonphosphorylatable mutant of CREB1 (S133A; Fig. 7, B and C). ChIP was performed with a ChIP grade anti-FLAG mouse antibody (Fig. 7D). Using real-time qPCR, we amplified three predicted CREB binding sites in the promoter of NHE6 (SLC9A6) at positions −12, +1, and +2 kb relative to the transcription start site (TSS) (Fig. 7D and Fig. S6D). For comparison, we used primers targeted to the NHE9 (SLC9A9) promoter at position −1 kb relative to TSS (Fig. 7E). We confirmed CREB binding to NHE6 promoter at all three predicted sites (Fig. 7, F–H). In contrast, we observed no significant binding of CREB to the NHE9 promoter (Fig. 7I). Specific pulldown of CREB1 was confirmed by probing the ChIP samples with an antibody against CREB raised in rabbits (Fig. 7J). Consistent with our ChIP-qPCR findings, we note that the pattern of NHE6 expression closely parallels that of CREB1 through normal human brain development (Fig. S7K; Pearson correlation, 0.62) and in all areas of the brain (Fig. 7L). In contrast, NHE9 expression showed no correlation with CREB (Fig. 7M; Pearson correlation, −0.018). Taken together, our findings reveal a novel mechanism of CRE-mediated transcriptional regulation of NHE6 and provide a molecular mechanism for nutrient- and HDAC-dependent regulation of endosomal pH.

**Control of NHE6 expression by pharmacological targeting of CREB pathway**

Christianson syndrome patients, with loss of function mutations in NHE6, clinically present with neurodevelopmental disorders of intellectual disability and severe autism and show age-dependent hallmarks of neurodegeneration, including loss of...
Histone deacetylases control endolysosomal pH

A

HEK293
CREB1-Flag expression
CREB1 pull-down
NHE6 gene expression
Functional assessment
Endosomal pH
NHE6 promoter occupancy

B

Empty vector
CREB1
CREB1 S133A
NHE6 expression (fold change)

C

Empty vector
CREB1
CREB1 S133A
Endosomal pH

D

NHE6/SLC9A6 gene promoter
ChrX:135,047,586
(-)12A
(+)+01A (+)+02A

E

NHE6/SLC9A9 gene promoter
Chr3:143,557,346
(-)01A

F

Control
CREB
Relative fold enrichment
SLC9A6 (-)12A

G

Control
CREB
Relative fold enrichment
SLC9A6 (+)01A

H

Control
CREB
Relative fold enrichment
SLC9A6 (+)02A

I

Control
CREB
Relative fold enrichment
SLC9A9 (-)01A

J

K

Corr. = 0.62, n = 244
P-value = 2.4x10^{-27}

L

NHE3 expression (Log2 RPKM)
CREB1 expression (Log2 RPKM)

M

Corr. = -0.018, n = 244
P-value = 0.762
Histone deacetylases control endolysosomal pH

The discovery of eNHE in the mid-1990s and subsequent work in a range of model organisms and mammalian systems have established the fundamental importance of these ion transporters in human health and disease (3, 63). Although the contribution of the V-ATPase in nutrient control of endolysosomal pH is well established in yeast (20, 21), the role of eNHE in this mechanism was previously unknown. Here, we leveraged public data from yeast, fly, and mammalian studies to make an unbiased in silico prediction leading to the discovery of an evolutionarily conserved mechanism for regulation of eNHE expression by nutrients and HDACs. Previous studies have established that glucose triggers rapid, post-translational regulation of disassembly and reassembly of V-ATPase to regulate the pH gradient across yeast vacuoles (20, 21). In this study, we show that glucose also elicits reciprocal transcriptional changes in Nhx1 and V-ATPase subunits to control vacuolar pH. This finding is in agreement with previous work showing severely reduced survival of Nhx1 mutants during nutrient-depleted stationary phase (19).

The regulation of endolysosomal pH by Nhx1 and V-ATPase (or their orthologs in higher eukaryotes) might promote cell survival during nutrient depletion or starvation by at least three potential mechanisms, as follows. (i) Vacuole acidity facilitates proton-dependent import of amino acids into the lumen through Avt1, a neutral amino acid transporter important for starvation resistance (18, 64). In nutrient-depleted cells, a decrease in vacuolar acidification would reduce vacuolar import of amino acids and help maintain cytoplasmic amino acid homeostasis (Fig. S8, A and B). (ii) Transcriptional control of V-ATPase subunits could supplement post-translational mechanisms of V-ATPase disassembly as an energy-saving mechanism to conserve ATP under nutrient-limiting conditions. (iii) We have previously shown that Nhx1 regulates vesi-

cerebellar and cortical mass, prominent glial pathlogy, and hyperphosphorylated Tau deposition (3, 51–53). Recent revelations on the shared pathology of defective Aβ clearance and altered processing of amyloid precursor protein between autism and Alzheimer’s disease suggest that endosomal pH regulation may be one critical mechanistic link between neurodevelopmental and neurodegenerative disorders (54). NHE6 gene expression is depressed in both AD and autism (55, 56). CREMediated transcriptional regulation of NHE6 expression offers opportunities to expand the repertoire of drugs that could potentially correct human pathologies resulting from NHE6 down-regulation and aberrant endosomal hyperacidification (Fig. 8A). For example, rolipram, a PDE4 inhibitor that elevates cAMP levels, resulting in CREB activation, has shown efficacy as memory enhancer and for amelioration of Aβ-related neuropathology in mouse models (57).

We used mouse astrocytes with knock-in of human ApoE alleles that alter genetic risk for Alzheimer’s disease (58). Recently, we showed that NHE6 expression is severely reduced in astrocytes carrying the pathological apoE4 variant, relative to the isogenic nonrisk ApoE3 allele (8). Consistent with this observation, CREB is down-regulated in apoE4 brains (59). First, we confirmed CREB-mediated NHE6 regulation in apoE3 astrocytes using the CREB inhibitor (KG501); we observed dose-dependent down-regulation of NHE6 transcript levels with KG501 treatment (Fig. 8D). Rolipram was effective in dose-dependent activation of CREB targets in apoE4 astrocytes, including the prototypic CREB target BDNF (Fig. S7,A), and astrocyte-specific CREB targets, ALDH1A1 and FBXO2 (60) (Fig. S7, B and C). We observed significant induction of CREB mRNA by rolipram as well (Fig. 8C), consistent with similar observations in rat hippocampus (61). Here, we demonstrate a dose-dependent increase in NHE6 transcript levels with rolipram treatment (1.25–10 μM) in apoE4 astrocytes (Fig. 8D). To evaluate the efficacy of rolipram treatment on NHE6-mediated function, we monitored Aβ clearance by endocytosis in cultured apoE4 astrocytes. Cell-associated Aβ was monitored using flow cytometry and confocal microscopy following a short (1-h) incubation with fluorescently tagged peptide (58, 62) (Fig. 8E). We show that rolipram elicits a significant increase in Aβ clearance, evidenced by an increase in cell-associated fluorescence by flow cytometry of apoE4 astrocytes (Fig. 8F). Similarly, endocytosed Aβ, monitored by confocal microscopy, exhibited an average of 2.66-fold increase following treatment with rolipram (Fig. 8, G and H). Although the increase in cell-associated Aβ could be, in part, due to a reduction in Aβ degradation, especially at longer time points, our experimental conditions are consistent with increased Aβ uptake. Taken together, our findings suggest that CREB activation of NHE6 expression is translatable into correction of Aβ clearance deficits in apoE4 astrocytes.

Discussion

Nutrient control of endolysosomal pH

Figure 7. CREB-mediated transcriptional regulation of NHE6 expression. A, experimental framework to directly test whether NHE6 is a CREB target. FLAG-tagged CREB1 plasmid was expressed in HEK293 cells and (i) NHE6 expression and its functional outcome (elevation of endosomal pH) and (ii) binding of CREB to NHE6 promoter by ChIP were assessed. B and C, expression of CREB1 in HEK293 cells significantly elevated NHE6 transcript (***, p < 0.0001; n = 3; Student’s t test; B), resulting in alkalization of endosomal pH from 5.9 ± 0.03 to 6.12 ± 0.05 (***, p = 0.0075; n = 3; Student’s t test; C). No changes in NHE6 transcript (p = 0.636; n = 3; Student’s t test; B) or endosomal pH (p = 0.916; n = 3; Student’s t test; C) were observed with the nonphosphorylatable mutant of CREB1 (S133A). D and E, schematic of NHE6 (top; D) and NHE9 (bottom; E) promoter element showing transcription start site, CREB-binding sites, and locations of ChIP-qPCR assays. F–H, CREB–ChIP-qPCR amplification of three predicted CREB-binding sites in the promoter of NHE6 at positions −12, +1, and +2 kb relative to the TSS in HEK293 cells. Note significant CREB binding to the NHE6 promoter at all three predicted sites. I, no significant binding of CREB to NHE9 promoter was identified using a primer targeting position −1 kb relative to the TSS. J, Western blotting to confirm specific pulldown of CREB1 by probing the ChIP samples from HEK293 cells with an antibody against CREB1 raised in rabbits. ChIP was performed using an antibody raised in mice. Note the high-molecular weight smear due to formaldehyde cross-linking. K and L, the pattern of NHE6 expression closely parallels that of CREB1 through normal human brain development (K) (Pearson correlation, 0.62; n = 244, ****, p < 0.0001) and in all areas of the brain (L, DFC, dorsolateral prefrontal cortex (CTX) (Brodmann area 9 (BA9), BA46); VFC, ventrolateral prefrontal cortex (BA44, BA45); MFC, medial prefrontal cortex (BA10, BA11, BA12); OFC, orbitofrontal cortex (BA11); M1C, primary motor cortex (CTX); S1C, primary somatosensory cortex (BA1–3); IPC, posterior inferior parietal cortex (BA1–4); A1C, primary auditory cortex (BA1–4); 1TC, posterior superior temporal cortical (BA22); IT1C, inferior temporal cortex (BA21); HIP, hippocampal formation; AMY, amygdaloid complex; STR, striatum; MDT, mediodorsal nucleus of thalamus; CBC, cerebellar cortex. M, NHE9 expression showed no correlation with CREB1 (Pearson correlation, −0.018; n = 244, p = 0.782). Data were obtained from the Allen Brain Atlas. NS, not significant. Error bars, S.D. See related Fig. 8.
Histone deacetylases control endolysosomal pH

A

AMP → PDE4 → cAMP → PKA → ATP → AC

ROL → HDACi → HDAC

CREB → CREB Φ → NHE6

FOR

B

DMSO
C

CREB inhibitor (KG501) 50μM
CREB inhibitor (KG501) 100μM

C

DMSO

Rolipram 1.25μM
Rolipram 2.5μM
Rolipram 5μM
Rolipram 10μM

E

Aβ clearance

Flow cytometry

DMSO or Rolipram

ApoE4 astrocyte culture

DMSO

Rolipram

F

G

Confocal microscopy

H

DMSO
Rolipram

Normalized Aβ clearance

Normalized Aβ fluorescence
ucle trafficking and lysosomal biogenesis to control internalization of plasma membrane proteins and degradation in vacuoles (15, 63). Increased Nhxl expression in glucose-depleted cells might therefore help promote endocytosis and provide resources for survival during glucose starvation (65). Intriguingly, eNHE mutants in Caenorhabditis elegans (Nhxl5) and fly (DmNhxl3) were found to be resistant to metformin, a biguanide drug commonly used to treat type-2 diabetes, potentially through dysregulation of autophagy (66). Given that metformin is known to induce a caloric restriction-like state (67), our findings suggest that up-regulation of eNHE and alkalization of endosomal pH may underlie response to metformin therapy.

**Antifungal drugs target endolysosomal pH**

Pathogenic fungi have become a leading cause of morbidity and mortality in the world (68). Fungi need V-ATPase function to infect their hosts, and genetic inactivation of vacuole-specific Vₒ subunit Vph1, but not secretory pathway-specific subunit Ste1, abolished virulence and invasive growth of C. albicans, underscoring the importance of endolysosomal pH as a drug target (16, 17). Consistent with this finding, the antifungal activity of azoles, which inhibit biosynthesis of fungus-specific sterol, ergosterol, is mediated by reduced V-ATPase activity in ergosterol-deficient vacuoles (31). Similarly, decreased V-ATPase activity may underlie the antifungal activity of amphotericin B, which is known to directly bind and sequester ergosterol in yeast cells (69). Furthermore, many naturally occurring antifungal compounds, such as terpenoid phenols, function at least in part by disrupting V-ATPase function (70). Recent studies have documented the potential benefits of repurposing FDA-approved amphiathic drugs, such as amiodarone, already in clinical use as calcium antagonists, that partition into acidic compartments, alkalize endolysosomes, and potentiate antifungal effects and reverse resistance toazole drugs (71). Here we show that an antifungal HDAC inhibitor, TSA, increases vacuole pH and enhances the antifungal effects of flucanazole. Intriguingly, both amiodarone and HDAC inhibitors confer significant neuroprotection in cell culture and animal models (11, 12, 72). Together, these studies and our current findings makes a strong case for (i) repurposing antifungal drugs as potential drugs to correct human pathologies arising from dysregulation of endolysosomal pH and (ii) repurposing FDA-approved drugs having off-target effects on pH homeostasis as candidates for the development of new therapeutic strategies for fungal disease.

**Histone deacetylases control endolysosomal pH**

Dysregulation of endolysosomal pH is an emerging theme in pathogenesis of a wide range of human diseases, ranging from neurodegeneration to cancer (7, 73). There is clearly potential for intervention to exploit the disease-modifying effects of endosomal pH, and this should be investigated further. From lessons learned with bakers’ yeast, we know that gene disruption of NHXL1 leads to cellular phenotypes reminiscent of Alzheimer’s disease (AD) that include an enlarged endosome/pre-vacuolar compartment, hyperacidic luminal pH, enhanced proteolysis of the chaperone protein Vps10 (a homolog of the AD susceptibility factor SORL1), mistrafficking of vacuolar hydrolases, and profound deficiencies in lysosomal cargo delivery (15, 74). Several studies have identified links between eNHE and a host of neurological disorders, including autism, intellectual disability, epilepsy, Parkinson’s disease, multiple sclerosis, and more recently late-onset AD (3, 8, 55, 75), although mechanisms underlying eNHE regulation have remained obscure. Here we show that expression of the Christianson syndrome protein NHE6 is under the control of CREB transcription factor. A translatable finding from our studies is that pharmacological HDAC inhibition (by TSA) or CREB activation (by forskolin or rolipram) elevates endosomal pH and has the potential to mitigate human pathologies, such as AD and autism, associated with aberrant endosomal hyperacidification. Furthermore, regulation of endolysosomal pH may at least partially explain the working mechanism of HDAC inhibitors in cancer therapy. Tumor cells in the periphery have better blood supply, whereas cells inside tumor masses are under starved conditions, because nutrients are not fully supplied to these cells. As we have shown earlier, a subset of brain cancer glioblastoma multiforme show significant up-regulation of eNHE isoform NHE9 that might help in the survival of tumor cells in nutrient-limited conditions (76). Together, these data suggest that, by governing fundamentally critical endosomal pH homeostasis, eNHE plays an important role in mediating nutrient control of endolysosomal pH. This importance makes them an attractive target as antifungal drugs and in several human diseases. Exploration of the conserved mechanism for regulation of endolysosomal pH by histone deacetylases provides a foundation for understanding the pathways regulating pH homeostasis and a platform for the development of drugs that could potentially correct human pathologies resulting from dysregulated endolysosomal acidification.

**Figure 8. Control of NHE6 expression by pharmacological targeting of CREB pathway.** A, extracellular signals induce adenylyl cyclase, which elevates cAMP levels and activates the cAMP-dependent protein kinase A (PKA), which in turn induces CREB phosphorylation at serine 133. Active phospho-CREB translocates to the nucleus and activates transcription of NHE6, which contains CRE in its promoter. At least three different pharmacological approaches could be used to activate CREB and enhance NHE6 transcription. First, HDAC inhibitors (HDACi) activate CREB by attenuating HDAC-mediated repression. Second, forskolin (FOR), an agonist of adenyl cyclase, stimulates production of CAMP and activates CREB. Third, rolipram (ROL), a PDE4 inhibitor, inhibits hydrolysis of CAMP and activates CREB. B, qPCR analysis to confirm CREB-mediated NHE6 regulation in apoE3 astrocytes using the CREB inhibitor (KG501). Note the dose-dependent down-regulation of NHE6 transcript levels with KG501 treatment (***, p < 0.0001; n = 3; Student’s t test). C, qPCR analysis demonstrating dose-dependent increase in CREB1 transcript levels with rolipram treatment in apoE4 astrocytes. D, qPCR analysis to demonstrate dose-dependent increase in NHE6 transcript levels with rolipram treatment (1.25–10 µM) in apoE4 astrocytes (***, p < 0.0001; n = 3; Student’s t test). E, fluorescence-based assay to monitor clearance of Aβ peptides by apoE4 astrocytes. F, quantitation of Aβ clearance from FACS analysis of 10,000 cells in biological triplicates confirmed restoration of Aβ clearance in apoE4 astrocytes with rolipram treatment (***, p < 0.0001; n = 3; Student’s t test), G and H, representative micrographs (G) and quantification (H) showing a ~2.66-fold increase in cell-associated Aβ in apoE4 astrocytes with rolipram treatment (***, p < 0.0001; n = 160/condition; Student’s t test). Error bars, S.D. See related Fig. S7.
Histone deacetylases control endolysosomal pH

Experimental procedures

Yeast strains and growth

All S. cerevisiae strains used were derivatives of BY4741 (a gift from Dr. Susan Michaelis (The Johns Hopkins University) or purchased from transOMIC Technologies). Yeast cells were grown in YPD (yeast extract, peptone, and dextrose) medium at 30 °C with shaking at 250 rpm. Acute glucose depletion was performed by growing yeast in in YP (yeast extract and peptone) medium. Yeast growth was determined by A<sub>600</sub>. A spotting assay on YPD agar plates was performed to detect drug-induced growth inhibition phenotypes.

Alkaline pH sensitivity and quinacrine staining

Increased luminal pH in the yeast vacuole was detected using two defining phenotypes: alkaline pH sensitivity and loss of quinacrine fluorescence. Sensitivity to alkaline medium pH was assayed in YPD medium, which was adjusted to pH 7 or pH 4.3. For quinacrine staining, cells were suspended in YPD medium containing 100 mM HEPES, pH 7.6, 200 μM quinacrine and stained for 10 min at 30 °C. Stained cells were washed three times with 100 mM HEPES, pH 7.6, 0.2% glucose and examined for 10 min at 37 °C. Stained cells were washed three times with 100 mM HEPES, pH 7.6, 0.2% glucose and examined by fluorescence microscopy immediately. Quantification of images was done using ImageJ software.

Cell culture

Human ApoE isoform-expressing (apoE3 and apoE4) immortalized astrocytes (gift from Dr. David M Holtzman, Washington University, St. Louis) were maintained in DMEM/F-12 (Invitrogen) supplemented with 10% fetal bovine serum. Culture conditions were in a 5% CO<sub>2</sub> incubator at 37 °C. Cell viability was measured using the trypan blue exclusion method.

Aβ clearance assays

To quantify Aβ clearance, apoE4 astrocytes were washed with serum-free medium followed by incubation with 100 nM fluorescently labeled HiLyte Fluor 647–Aβ40 (AS-64161, AnaSpec). Following several washes with PBS, cells were fixed for confocal imaging using the LSM 700 confocal microscope (Zeiss) or trypsinized for flow cytometry analysis of ~10,000 cells in biological triplicates using the FACS Calibur instrument (BD Biosciences). Unstained cells without any exposure to fluorescently labeled Aβ were used as a control for background fluorescence. Quantification of confocal images was done using ImageJ software.

Antibodies and reagents

ChIP grade mouse monoclonal anti-FLAG (M2) (F3165) and rabbit monoclonal anti-CREB (48H2) (9197) were obtained from Sigma and Cell Signaling Technology, respectively. TSA (A8183) was from ApexBio Technology. Concanamycin A (C9705), fluconazole (F8929), KG501 (70485), and rolipram (R6520) were obtained from Sigma. Forskolin (3828) was purchased from Cell Signaling Technology.

Plasmids and transfection

pBY011 Rpd3 plasmid under galactose inducible promoter was obtained from Harvard PlasmID Repository (ScCD00010538). Empty vector with uracil resistance was a gift of Dr. Steven Claypool (The Johns Hopkins University). Yeast transformation was performed using the lithium acetate method. pCF CREB1 (Addgene plasmid 22968) and pCF CREB1 S133A (Addgene plasmid 22969) were a gift from Dr. Marc Montminy. pcDNA-HDAC4 (S246A/S467A/S632A) (Addgene plasmid 30486) was a gift from Dr. Tso-Pang Yao. HEK293T cells were transfected using Lipofectamine 2000 reagent as per the manufacturer’s instructions.

Quantitative real-time PCR

mRNA was extracted from yeast and cell cultures using the RNeasy minikit (74104, Qiagen) with DNase I (10104159001, Roche Applied Science) treatment, following the manufacturer’s instructions. Yeast lysis buffer contained 1 M sorbitol, 0.1 M EDTA, 0.1% β-mercaptoethanol, and zymolase (E1004, Zymo Research). Complementary DNA was synthesized using the high-capacity RNA-to-cDNA kit (4387406, Applied Biosystems). Quantitative real-time PCR analysis was performed using the 7500 real-time PCR system (Applied Biosystems) using Taqman Fast universal PCR Master Mix (4320242, Applied Biosystems). Taqman gene expression assay probes used in this study are as follows: yeast: ACT1, Sc04120488_s1; NHXI, Sc04115315_s1; RPD3, Sc04161394_s1; STV1, Sc04135492_s1; VMA1, Sc04108170_s1; VMA7, Sc04124849_s1; human: ATP6V0A1, Hs00989334_m1; ATP6V0A2, Hs00429389_m1; GAPDH, Hs02786624_g1; NHE1, Hs00234723_m1; NHE7, Hs01078624_m1; NHE9, Hs00543518_m1; mouse: ALDH1A1, Mm00657317_m1; BDNF, Mm01205734_m1; CREB1, Mm00510167_m1; FBXO2, Mm00805188_g1; GAPDH, Mm99999915_g1; NHE6, Mm0055445_m1. The Ct (cycle threshold) values were first normalized to endogenous control levels by calculating the ΔCt for each sample. These values were then analyzed relative to control, to generate a ΔΔCt value.

Endosomal pH measurement

Endosomal pH was measured using flow cytometry, as we described previously (55, 75). Briefly, cells were rinsed and incubated in serum-free medium for 30 min to remove residual transferrin and then incubated with pH-sensitive FITC-transferrin (T2871, Thermo Fisher Scientific) (75 μg/ml) together with pH-nonsensitive Alexa Fluor 633–transferrin (T23362, Thermo Fisher Scientific) (25 μg/ml) at 37 °C for 1 h. Cells were placed on ice to stop transferrin uptake, and excess transferrin was removed by washing twice with ice-cold serum-free DMEM and PBS. Bound transferrin was removed by washing with ice-cold PBS, pH 5.0, and PBS, pH 7.0. Cells were trypsinized, and pH was determined by flow cytometry analysis of ~10,000 cells in biological triplicates using the FACS Calibur instrument (BD Biosciences). A four-point calibration curve with different pH values (4.5, 5.5, 6.5, and 7.5) was generated using the Intracellular pH Calibration Buffer Kit (P35379, 6732 J. Biol. Chem. (2018) 293(18) 6721–6735
Thermo Fisher Scientific) in the presence of 10 μM K+/H+ ionophore nigericin and 10 μM K+ ionophore valinomycin.

**Bioinformatics**

An unbiased in silico approach was used to identify experimental conditions that significantly altered NhX1 expression, by analyzing data from 284 *Saccharomyces cerevisiae* microarray studies, which comprised a wide range of studies, including gene deletion, overexpression and mutations, drug/toxin treatment, nutrient limitation or excess, metabolic/environmental stress, and many others. Experimental conditions with a minimum gene expression -fold change of ±2 were selected for further thorough pathway analysis. A predictive model for regulation of NhX1 expression was created based on the overlap of pathways from experimental conditions that resulted in the highest degree of changes in gene expression (both up- and down-regulation) and selected for in vitro validation. Meta-analysis of 45 microarray experiments, including 937 samples, determined the effect of growth phase on NhX1 expression. Normalized yeast expression data were obtained from Genevestigator (Nebion AG). *Drosophila* microarray experiment GSE14531 was analyzed to study the starvation effect on fly larvae. Mammalian gene expression data sets included in the study were GSE11291, GSE8488, and GSE9247. Human brain and *Drosophila* gene expression data were obtained from the Allen Brain and FlyBase atlas, respectively.

**ChIP-qPCR**

To assess physical binding of the FLAG-tagged CREB to the NHE6 gene promoter, ChIP-qPCR was carried out. ChIP was performed using the EpiQuik ChIP kit (P-2002, Epigentek), according to the manufacturer’s instructions. In brief, cells were treated with 1% formaldehyde for 10 min to cross-link proteins to DNA. To generate DNA fragments ~200–1,000 base pairs long, the cross-linked chromatin was sonicated on ice. ChIP assays were performed using a ChIP grade anti-FLAG antibody. Specific pulldown of CREB1 was confirmed by probing the ChIP samples with an antibody against CREB raised in rabbits using Western blotting. After reversal of the cross-links, qPCR was performed using the EpiTect ChIP-qPCR primer assay for NHE6/SLC9A6 (GPH1013950(−)12A, −12 kb from the transcription start site; GPH1013950(+101A, +1 kb from the transcription start site; and GPH1013950(+02A, +2 kb from the transcription start site). The ChIP-qPCR primer assay for the NHE9/SLC9A9 promoter (GPH1023313(−)101A, −1 kb from the transcription start site) was used as a control (all Qiagen). The resulting amplification and melt curves were analyzed to ensure specific PCR product. Ct values were used to calculate the -fold enhancement.

**Luciferase assay**

pCRE-Luc (encoding for CRE and firefly luciferase) and pSV40-RL (encoding for an SV40 promoter and *Renilla* luciferase) plasmids (gift of Dr. Jennifer L. Pluznick, The Johns Hopkins University) were transiently transfected into HEK293T cells using Lipofectamine 2000 reagent, as per the manufacturer’s instructions. The ratio of firefly luciferase and *Renilla* luciferase was measured using the Dual-Luciferase assay system (E1910, Promega) with data collected using a FLUOstar Omega automated plate reader (BMG LabTech) to evaluate the CREB activation following treatment with an HDAC inhibitor.

**Author contributions**—H. P. designed, conducted, and analyzed experiments and wrote the paper. R. R. designed and interpreted experiments and wrote the paper.

**Acknowledgments**—We thank Dr. David M. Holtzman (Washington University, St. Louis, MO) for the gift of apoE immortalized astrocytes. We thank Dr. Susan Michaelis, Dr. Steven Claypool, and Dr. Jennifer L. Pluznick (The Johns Hopkins University) for yeast strains and plasmids.

**References**

1. Maxfield, F. R. (2014) Role of endosomes and lysosomes in human disease. *Cold Spring Harb. Perspect. Biol.* 6, a016931 CrossRef Medline

2. Casey, J. R., Grinstein, S., and Orlowski, J. (2010) Sensors and regulators of intracellular pH. *Nat. Rev. Mol. Cell Biol.* 11, 50–61 CrossRef Medline

3. Kondapalli, K. C., Prasad, H., and Rao, R. (2014) An inside job: how endosomal Na+/H+ exchangers link to autism and neurological disease. *Front. Cell. Neurosci.* 8, 172 Medline

4. Picollo, A., and Pusch, M. (2005) Chloride/proton antiporter activity of mammalian CLC proteins CIC-4 and CIC-5. *Nature* 436, 420–423 CrossRef Medline

5. Lee, C., Kang, H. J., von Ballmoos, S., Uzdavinys, P., Dotson, D. L., Ivata, S., Beckstein, O., Cameron, A. D., and Drew, D. (2013) A two-domain elevator mechanism for sodium/proton antiporter. *Nature* 501, 573–577 CrossRef Medline

6. Esmail, S., Kartner, N., Yao, Y., Kim, J. W., Reithmeier, R. A. F., and Manolagas, S. C. (2018) Molecular mechanisms of calcitriol and distal renal tubular acidosis-causing mutations in V-ATPase subunits, ATP6V0A2 and ATP6V0A4. *J. Biol. Chem.* 293, 2787–2800 CrossRef Medline

7. Colaccurcio, D. J., and Nixon, R. A. (2016) Disorders of lysosomal acidification: the emerging role of V-ATPase in aging and neurodegenerative disease. *Ageing Res. Rev.* 32, 75–88 CrossRef Medline

8. Prasad, H., and Rao, R. (2018) The amyloid clearance defect in apoE astrocytes is corrected by epigenetic restoration of NHE6. *bioRxiv* 243097 CrossRef

9. Treusch, S., Hamamichi, S., Goodman, J. L., Matlack, K. E., Chung, C. Y., Baru, V., Shulman, J. M., Parrado, A., Bevis, B. J., Valastyan, J. S., Han, H., Lindhagen-Persson, M., Reiman, E. M., Evans, D. A., Bennett, D. A., et al. (2011) Functional links between Abeta toxicity, endocytic trafficking, and Alzheimer’s disease risk factors in yeast. *Science* 334, 1241–1245 CrossRef Medline

10. Seto, E., and Yoshida, M. (2014) Erasers of histone acetylation: the histone deacetylase enzymes. *Cold Spring Harb. Perspect. Biol.* 6, a018713 CrossRef Medline

11. Gräff, J., Rei, D., Guan, J. S., Wang, W. Y., Jeo, J., Hennig, K. M., Nieland, T. J., Fass, D. M., Kao, P. F., Kahn, M., Su, S. C., Samiei, A., Joseph, N., Haggarty, S. J., Delalle, I., and Tsai, L. H. (2012) An epigenetic blockade of cognitive functions in the neurodegenerating brain. *Nature* 483, 222–226 CrossRef Medline

12. Veesey, C. G., Haw, J. D., Lattal, K. M., Stein, J. M., Fabian, S. A., Attner, M. A., Cabrera, S. M., McDonough, C. B., Brindle, P. K., Abel, T., and Wood, M. A. (2007) Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB-CBP-dependent transcriptional activation. *J. Neurosci.* 27, 6128–6140 CrossRef Medline

13. Makena, M. R., Koneru, B., Nguyen, T. H., Kang, M. H., and Reynolds, C. P. (2017) Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies. *Mol. Cancer Ther.* 16, 649–661 CrossRef Medline

14. Dinarello, C. A., Fossati, G., and Mascagni, P. (2011) Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. *Mol. Med.* 17, 333–352 CrossRef Medline
Histone deacetylases control endolysosomal pH

15. Brett, C. L., Tukoyer, D. N., Mukherjee, S., and Rao, R. (2005) The yeast endosomal Na⁺ K⁺ H⁺ exchanger Nhx1 regulates cellular pH to control vesicle trafficking. Mol. Biol. Cell 16, 1396–1405 CrossRef Medline

16. Patenaude, C., Zhang, Y., Cormack, B., Köhler, J., and Rao, R. (2013) Essential role for vascular acidification in Candida albicans virulence. J. Biol. Chem. 288, 26256–26264 CrossRef Medline

17. Tarsio, M., Zheng, H., Smardon, A. M., Martínez-Muñoz, G. A., and Kane, P. M. (2011) Consequences of loss of Vph1 protein-containing vacuolar ATPases (V-ATPases) for overall cellular pH homeostasis. J. Biol. Chem. 286, 28089–28096 CrossRef Medline

18. Hughes, A. L., and Gottschling, D. E. (2012) An early age increase in vacuolar pH limits mitochondrial function and lifespan in yeast. Nature 492, 261–265 CrossRef Medline

19. Numata, M., Petrecca, K., Lake, N., and Ornslowski, J. (1998) Identification of a mitochondrial Na⁺ /H⁺ exchanger. J. Biol. Chem. 273, 6951–6959 CrossRef Medline

20. Kane, P. M. (1995) Disassembly and reassembly of the yeast vacuolar H⁺-ATPase in vivo. J. Biol. Chem. 270, 17025–17032 Medline

21. Kane, P. M., and Parra, K. J. (2000) Assembly and regulation of the yeast vacuolar H⁺-ATPase. J. Biol. Chem. 275, 203, 81–87 Medline

22. Pnueli, L., Edry, I., Cohen, M., and Kassir, Y. (2004) Glucose and nitrogen regulate the switch from histone deacetylation to acetylation for expression of early meiosis-specific genes in budding yeast. Mol. Cell. Biol. 24, 5197–5208 CrossRef Medline

23. Bernstein, B. E., Tong, J. K., and Schreiber, S. L. (2000) Genomewide study of histone deacetylase and SAGA, and TATA binding protein. Mol. Cell. Biol. 20, 6458–6470 CrossRef Medline

24. Yarragudi, A., Parfrey, L. W., and Morse, R. H. (2007) Genomic analysis of transcriptional dependence and probable target sites for Abf1 and Rap1 in Saccharomyces cerevisiae. Nucleic Acids Res. 35, 193–202 CrossRef Medline

25. Leonov, A., Feldman, R., Piano, A., Arla–Ciommo, A., Lutchman, V., Ahmadi, M., Elsasser, S., Fakim, H., Heshmati-Moghaddam, M., Hussain, A., Orfali, S., Rajen, H., Rodigari-Esfahani, N., Rosanelli, L., and Titorenko, V. I. (2017) Caloric restriction extends yeast chronological lifespan via a mechanism linking cellular aging to cell cycle regulation, maintenance of a quiescent state, entry into a non-quiescent state and survival in the non-quiescent state. Oncotarget 8, 69328–69350 Medline

26. Deckert, J., and Struhl, K. (2002) Targeted recruitment of Rpd3 histone deacetylases represses transcription by inhibiting recruitment of Swi/Snf, SAGA, and TATA binding protein. Mol. Cell. Biol. 22, 6458–6470 CrossRef Medline

27. Sambade, M., Alba, M., Smardon, A. M., West, R. W., and Kane, P. M. (2005) A genomic screen for yeast vacuolar membrane ATPase mutants. Genetics 170, 1539–1551 CrossRef Medline

28. Brett, C. L., Donowitz, M., and Rao, R. (2005) Evolutionary origins of eukaryotic sodium/proton exchangers. Am. J. Physiol. Cell Physiol. 288, C223–C239 CrossRef Medline

29. Palanker, L., Tennessen, J. M., Lam, G., and Thummel, C. S. (2009) Drosophila HNF4 regulates lipid mobilization and β-oxidation. Cell Metab. 9, 228–239 CrossRef Medline

30. Mihaylova, M. M., Vasquez, D. S., Ravenkjaer, K., Denecaud, P. D., Yu, R. T., Alvarez, J. G., Downes, M., Evans, R. M., Montminy, M., and Shaw, R. J. (2011) Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145, 607–621 CrossRef Medline

31. Johnson, M. L., Distelmaier, K., Lanza, I. R., Irving, B. A., Robinson, M. M., Konopka, A. R., Shulman, G. I., and Nair, K. S. (2016) Mechanism by which caloric restriction improves insulin sensitivity in sedentary obese mice. Diabetes 65, 74–84 Medline

32. Li, Y., Daniel, M., and Tollefsbol, T. O. (2011) Epigenetic regulation of caloric restriction in aging. BMC Med. 9, 98 CrossRef Medline

33. Wheatley, K. E., Nogueira, L. M., Perkins, S. N., and Hurting, S. D. (2011) Differential effects of caloric restriction and exercise on the adipose transcriptional scriptome in diet-induced obese mice. J. Obes. 2011, 269417 CrossRef Medline

34. Fusco, S., Ripoli, C., Poddà, M. V., Ranieri, S. C., Leone, L., Toietta, G., McBurney, M. W., Schütz, G., Riccio, A., Grassi, C., Galeotti, T., and Pan, G. (2012) A role for neuronal cAMP responsive-element binding (CREB)-1 in brain responses to calorie restriction. Proc. Natl. Acad. Sci. U.S.A. 109, 621–626 CrossRef Medline

35. Prior, M. I., Larance, M., Lawrence, R. T., Soul, J., Humphrey, S., Burchfield, J. K., Cistler, C., Davey, J. R., La-Borde, P. J., Buckley, M., Kanazawa, H., Parton, R. G., Guilhaus, M., and James, D. E. (2011) Quantitative proteomic analysis of the adipocyte plasma membrane. J. Proteome Res. 10, 4970–4982 CrossRef Medline

36. Ouyang, Q., Lizarraga, S. B., Schmidt, M., Yang, G., Ellison, D., Kauer, J. A., and Morrow, E. M. (2013) Christianson syndrome protein NHE6 modulates Trkβ endosomal signaling required for neuronal circuit development. Neuron 80, 97–112 CrossRef Medline

37. Walton, M. R., and Dragunow, I. (2000) Is CREB a key to neuronal survival? Trends Neurosci. 23, 48–53 CrossRef Medline

38. Barger, J. L., Kayo, T., Vann, J. M., Arias, E. B., Wang, J., Hacker, T. A., Wang, Y., Raederstorff, D., Morrow, J. D., Leeuwenburgh, C., Allison, D. B., Sappe, K. W., Cartee, G. D., Weindruch, R., and Prolla, T. A. (2008) A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 3, e2264 CrossRef Medline

39. Schroeder, T. M., Nair, A. K., Staggs, R., Lamblin, A. F., and Westendorf, J. J. (2007) Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors. BMC Genomics 8, 362 CrossRef Medline

40. Ulici, V., James, C. G., Hoeneslær, K. D., and Beier, F. (2010) Regulation of gene expression by P38 kin in mouse growth plate chondrocytes. PLoS One 5, e8686 CrossRef Medline

41. Fusco, S., Leone, L., Barbati, S. A., Samengo, D., Piccentini, R., Mauclerc, G., Toietta, G., Spinnelli, M., McBurney, M., Panì, G., and Grassi, C. (2016) A CREB-Sirt1-Hes1 circuit mediates neural stem cell response to glucose availability. Cell Rep. 14, 1195–1205 CrossRef Medline

42. Canettieri, G., Morantte, I., Güzman, E., Asahara, H., Herzig, S., Anderson, S. D., Yates, J. R., 3rd, Montminy, M. (2003) Attenuation of a phosphorylation-dependent activator by an HDAC-1 PD1 complex. Nat. Struct. Biol. 10, 175–181 CrossRef Medline

43. Li, J., Chen, J., Ricuperto, C. L., Hart, R. P., Schwartz, M. S., Kusnecko, A., and Herrup, K. (2012) Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat. Med. 18, 783–790 CrossRef Medline

44. Silve, S., Rhode, P. R., Coll, B., Campbell, J., and Poyton, R. O. (1992) ABF1 is a phosphoprotein and plays a role in carbon source control of COX6 transcription in Saccharomyces cerevisiae. Mol. Cell. Biol. 12, 4197–4208 CrossRef Medline

45. Zhang, X., Odom, D. T., Koo, S. H., Conkright, M. D., Canettieri, G., Best, J., Chen, H., Jenner, R., Embolsholsemer, I., Jacobsen, E., Kadam, S., Ecker, J. R., Emerson, B., Hogeness, J. B., Unterman, T., et al. (2005) Genomewide analysis of CAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc. Natl. Acad. Sci. U.S.A. 102, 4459–4464 Medline
51. Garbern, J. Y., Neumann, M., Trojanowski, J. Q., Lee, V. M. F., Feldman, G., Norris, J. W., Friez, M. J., Schwartz, C. E., Stevenson, R., and Sima, A. A. (2010) A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition. *Brain* 133, 1391–1402 CrossRef Medline

52. Mignot, C., Héron, D., Bursztyn, J., Momtchilova, M., Mayer, M., Whalen, S., Legall, A., Billotte de Villemeur, T., and Burglen, L. (2013) Novel mutation in SLC9A6 gene in a patient with Christian syndrome and retinitis pigmentosum. *Brain Dev.* 35, 172–176 CrossRef Medline

53. Stromme, P., Dobrenis, K., Sillitoe, R. V., Guinello, M., Ali, N. F., Davidson, C., Micsenyi, M. C., Stepney, G., Ellevog, L., Klungland, A., and Walkley, S. U. (2011) X-linked Angelman-like syndrome caused by Slc9a6 knockout in mice exhibits evidence of endosomal-lysosomal dysfunction. *Brain* 134, 3369–3383 CrossRef Medline

54. Westmark, C. J., Sokol, D. K., Maloney, B., and Lahiri, D. K. (2016) Novel roles of amyloid-β precursor protein metabolites in fragile X syndrome and autism. *Mol. Psychiatry* 21, 1333–1341 CrossRef Medline

55. Prasad, H., and Rao, R. (2015) The Na+/H+ exchanger NHE6 modulates endosomal pH to control processing of amyloid precursor protein in a cell culture model of Alzheimer disease. *J. Biol. Chem.* 290, 5311–5327 CrossRef Medline

56. Schwede, M., Garbett, K., Mirnics, K., Geschwind, D. H., and Morrow, E. M. (2014) Genes for endosomal NHE6 and NHE9 are misregulated in autism brains. *Mol. Psychiatry* 19, 277–279 CrossRef Medline

57. Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., and Arancio, O. (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. *J. Clin. Invest.* 114, 1624–1634 CrossRef Medline

58. Verghese, P. B., Castellano, J. M., Gara, K., Wang, V., Jiang, H., Shah, A., Bu, G., Frieden, C., and Holtzman, D. M. (2013) ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. *Proc. Natl. Acad. Sci. U.S.A.* 110, E1807–E1816 CrossRef Medline

59. Qiao, F., Gao, X. P., Yuan, L., Cai, H. Y., and Qi, J. S. (2014) Apolipoprotein E4 impairs in vivo hippocampal long-term synaptic plasticity by reducing the phosphorylation of CaMKIIα and CREB. *J. Alzheimer's Dis.* 41, 1165–1176 Medline

60. Pardo, L., Schlüter, A., Valor, L. M., Barco, A., Giralt, M., Golbano, A., Hidalgo, J., Jia, P., Zhao, Z., Jové, M., Portero-Otín, M., Ruiz, M., Giménez-Llort, L., Masgrau, R., Pujol, A., and Galea, E. (2016) Targeted activation of CREB in reactive astrocytes is neuroprotective in focal acute cortical injury. *Glia* 64, 853–874 CrossRef Medline

61. Nibuya, M., Nestler, E. J., and Duman, R. S. (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. *J. Neurosci.* 16, 2365–2372 Medline

62. Nazer, B., Hong, S., and Selkoe, D. J. (2008) LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. *Neurobiol. Dis.* 30, 94–102 CrossRef Medline

63. Nass, R., and Rao, R. (1998) Novel localization of a Na+/H+ exchanger in a late endosomal compartment of yeast: implications for vacuole biogenesis. *J. Biol. Chem.* 273, 21054–21060 CrossRef Medline

64. Davey, H. M., Cross, E. J., Davey, C. L., Gkargkas, K., Delneri, D., Hoyle, D. C., Oliver, S. G., Kell, D. B., and Griffith, G. W. (2012) Genome-wide analysis of longevity in nutrient-deprived Saccharomyces cerevisiae reveals importance of recycling in maintaining cell viability. *Environ. Microbiol.* 14, 1249–1260 CrossRef Medline

65. Lang, M. J., Martinez-Marquez, J. Y., Prosser, D. C., Ganser, L. R., Buelto, D., Wendland, B., and Duncan, M. C. (2014) Glucose starvation inhibits autophagy via vacuolar hydrolysis and induces plasma membrane internalization by down-regulating recycling. *J. Biol. Chem.* 289, 16736–16747 CrossRef Medline

66. Davey, H. M., Cross, E. J., Davey, C. L., Gkargkas, K., Delneri, D., Hoyle, D. C., Oliver, S. G., Kell, D. B., and Griffith, G. W. (2012) Genome-wide analysis of longevity in nutrient-deprived Saccharomyces cerevisiae reveals importance of recycling in maintaining cell viability. *Environ. Microbiol.* 14, 1249–1260 CrossRef Medline

67. Kim, J., Lee, H. Y., Ahn, J., Hyun, M., Lee, I., Min, K. J., and You, Y. J. (2016) NHX-5, an endosomal Na+/H+ exchanger, is associated with metformin action. *J. Biol. Chem.* 291, 18591–18599 CrossRef Medline

68. Onken, B., and Driscoll, M. (2010) Metformin induces a dietary restriction-like state and the oxidative stress response to extend *C. elegans* healthspan via AMPK, LKB1, and SKN-1. *PloS One* 5, e8758 CrossRef Medline

69. Roemer, T., and Krysan, D. J. (2014) Antifungal drug development: challenges, unmet clinical needs, and new approaches. *Cold Spring Harb. Perspect. Med.* 4, a019703 CrossRef Medline

70. Gray, K. C., Palacios, D. S., Dailey, I., Endo, M. M., Uno, B. E., Wilcock, B. C., and Burke, M. D. (2012) Amphotericin primarily kills yeast by simply binding ergosterol. *Proc. Natl. Acad. Sci. U.S.A.* 109, 2234–2239 CrossRef Medline

71. Rao, A., Zhang, Y., Muend, S., and Rao, R. (2010) Mechanism of antifungal activity of terpenoid phenols resembles calcium stress and inhibition of the TOR pathway. *Antimicrob. Agents Chemother.* 54, 5062–5069 CrossRef Medline

72. da Silva, C. R., de Andrade Neto, J. B., Nilwakul, A., Magalhães, H. I., Cavalcanti, B. C., Brilhante, R. S., Macedo, D. S., de Moraes, M. O., Lobo, M. D., Grangeiro, T. B., and Nobre Júnior, H. V. (2013) Synergistic effects of amiodarone and fluconazole on Candida tropicalis resistant to fluconazole. *Antimicrob. Agents Chemother.* 57, 1691–1700 CrossRef Medline

73. Mitterreiter, S., Pagl, R. M., Kamp, F., Hopson, J., Winkler, E., Ha, H. R., Hamid, R., Herms, J., Mayer, T. U., Nelson, D. J., Steiner, H., Stahl, T., Zeitschel, U., Rossner, S., Haass, C., and Lichtenthaler, S. F. (2010) Bepridil action. *J. Neurosci.* 30, 11341–11348 CrossRef Medline

74. Nixon, R. A. (2005) Endosome function and dysfunction in Alzheimer’s disease. *Mol. Psychiatry* 10, 1333–1341 CrossRef Medline

75. Prasad, H., Osei-Owusu, J., and Rao, R. (2017) Functional analysis of NHE6 variants identified in patients with autism and epilepsy. *Mol. Psychiatry* 22, 2234–2239 CrossRef Medline

76. Kondapalli, K. C., Llongueras, J. P., Capilla-González, V., Prasad, H., Hack, A., Smith, C., Guerrero-Cañón, H., Quítones-Hinojosa, A., and Rao, R. (2015) A leak pathway for luminal protons in endosomes drives oncogenic signalling in glioblastoma. *Nat. Commun.* 6, 6289 CrossRef Medline

---

**Histone deacetylases control endolysosomal pH**

---

**J. Biol. Chem. (2018) 293(18) 6721–6735 6735**